Resitu Medical has closed the second seed round of 1,5 MEUR mainly by existing shareholders. Major shareholders are Novoaim 60%, ALMI Invest 15% and Stockholm Business Angels (STOAF) 15%. 

The development of the first instrument is proceeding according to plan. The product design is finalized and is currently being transferred to production. “The funding will be used to verification, validation, clinical studies, and prepare the documentation for CE mark and FDA submission” says CEO Stefan Sowa.